MARKET

CTMX

CTMX

Cytomx Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.690
0.000
0.00%
After Hours: 1.690 0 0.00% 16:19 05/19 EDT
OPEN
1.700
PREV CLOSE
1.690
HIGH
1.760
LOW
1.650
VOLUME
870.12K
TURNOVER
--
52 WEEK HIGH
8.95
52 WEEK LOW
1.510
MARKET CAP
110.52M
P/E (TTM)
-1.1994
1D
5D
1M
3M
1Y
5Y
--Wedbush Adjusts Price Target for CytomX Therapeutics to $6 From $10, Maintains Outperform Rating
MT Newswires · 05/10 15:12
CytomX Therapeutics (CTMX) Reports Q1 Loss, Lags Revenue Estimates
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -5.71% and 21.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 22:25
CytomX Therapeutics: Q1 Earnings Insights
CytomX Therapeutics (NASDAQ:CTMX) reported its Q1 earnings results on Thursday, May 5, 2022 at 04:15 PM. Here's what investors need to know about the announcement.
Benzinga · 05/05 22:07
CytomX Therapeutics Q1 EPS $(0.37) Misses $(0.36) Estimate, Sales $17.10M Miss $20.66M Estimate
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.36) by 2.78 percent. This is a 42.31 percent decrease over losses of $(0.26) per share
Benzinga · 05/05 21:52
CytomX GAAP EPS of -$0.37 misses by $0.01, revenue of $17.13M misses by $4.12M
CytomX press release (NASDAQ:CTMX): Q1 GAAP EPS of -$0.37 misses by $0.01. Revenue of $17.13M (+7.3% Y/Y) misses by $4.12M.
Seekingalpha · 05/05 20:25
-- Earnings Flash (CTMX) CYTOMX THERAPEUTICS Posts Q1 Revenue $17.1M, vs. Street Est of $21.2M
MT Newswires · 05/05 16:34
CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022
SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it will report first quarter 2022 financial results on Th...
GlobeNewswire · 04/28 12:00
OMIC, CTMX and LFST among after hour movers
Gainers:Singular Genomics Systems  (OMIC) +5%. Sonos  (SONO) +5%. Fulton Financial Corporation (FULT) +5%. CytomX Therapeutics (CTMX) +5%. Walgreens Boots Alliance (WBA) +4%. Losers: Netflix (NFLX) -26%. LifeStance Health Group (LFST) -8%. INMODE  (INMD)
Seekingalpha · 04/19 22:03
More
No Data
Learn about the latest financial forecast of CTMX. Analyze the recent business situations of Cytomx Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CTMX stock price target is 12.00 with a high estimate of 16.00 and a low estimate of 6.00.
High16.00
Average12.00
Low6.00
Current 1.690
EPS
Actual
Estimate
-0.32-0.24-0.16-0.08
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 179
Institutional Holdings: 57.60M
% Owned: 88.07%
Shares Outstanding: 65.40M
TypeInstitutionsShares
Increased
27
7.06M
New
23
9.26M
Decreased
44
6.22M
Sold Out
25
9.50M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.00%
Pharmaceuticals & Medical Research
+0.51%
Key Executives
Chairman/Chief Executive Officer/Director
Sean McCarthy
President/Chief Operating Officer
Amy Peterson
Chief Financial Officer/Senior Vice President
Carlos Campoy
Senior Vice President/Chief Compliance Officer/General Counsel/Secretary
Lloyd Rowland
Senior Vice President
Alison Hannah
Lead Director/Independent Director
Matthew Young
Director
Alan Ashworth
Independent Director
Halley Gilbert
Independent Director
Elaine Jones
Independent Director
James Meyers
Independent Director
Mani Mohindru
Independent Director
John Scarlett
No Data
No Data
About CTMX
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing a class of investigational conditionally activated therapeutics, based on its Probody technology platform, for the treatment of cancer. Its Probody technology platform is designed to enable conditional activation of antibody-based drugs in the tumor microenvironment while minimizing drug activity in healthy tissues and in circulation. The Company's product candidates include the conditionally activated antibody-drug conjugates (ADCs) praluzatamab ravtansine (CX2009, targeting CD166) and CX-2029, targeting CD71, and the Probody immune checkpoint inhibitors pacmilimab (CX-072, targeting PD-L1) and BMS-986249 (targeting CTLA-4). It also has two preclinical agents in investigational new drug (IND)-enabling studies - a conditionally activated ADC targeting EpCAM/Trop-1 (CX-2043) and a conditionally activated T-cell engaging bispecific antibody targeting EGFR and CD3 (CX-904).

Webull offers kinds of CytomX Therapeutics Inc stock information, including NASDAQ:CTMX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTMX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CTMX stock methods without spending real money on the virtual paper trading platform.